Statins are associated with a reduced risk of cholangiocarcinoma: A population-based case-control study

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 755-761

  Peng, Yen Chun ^a,b   Lin, Cheng Li ^c,d   Hsu, Wan Yun ^a   Chang, Chi Sen ^a   Yeh, Hong Zen ^a,b   Tung, Chun Fang ^a,b   Wu, Yuh Lin ^b   Sung, Fung Chang ^c,e   Kao, Chia Hung ^c,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

case control study; cholangiocarcinoma; insurance data; propensity score matching; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RISK; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; BILE DUCT NEOPLASMS; CASE CONTROL STUDY; CHOLANGIOCARCINOMA; DOSE RESPONSE; DRUG UTILIZATION; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TAIWAN;

AGED; BILE DUCT NEOPLASMS; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK ASSESSMENT; TAIWAN;

EID: 84942552262     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12641     Document Type: Article

References (41)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD,. Cholangiocarcinoma. Lancet 2005; 366: 1303-14.
2. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B, Hong ST,. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010; 101: 579-85.
3. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X, Willenbring H,. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012; 122: 2911-5.
4. Zucman-Rossi J, Nault JC, Zender L,. Primary liver carcinomas can originate from different cell types: a new level of complexity in hepatocarcinogenesis. Gastroenterology 2013; 145: 53-5.
5. Blechacz B, Komuta M, Roskams T, Gores GJ,. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 512-22.
6. Patel T,. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 33-42.
7. Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ, Roberts RO, Olson JE, Therneau TM, Roberts LR,. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013; 57: 648-55.
8. Yu TH, Yuan RH, Chen YL, Yang WC, Hsu HC, Jeng YM,. Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression. Mod Pathol 2011; 24: 810-9.
9. Burr NE, Talboys RJ, Savva S, Clark A, Phillips M, Metcalfe M, Dennison A, Robinson R, Lewis MP, Rhodes M, Rushbrook S, Hart AR,. Aspirin may prevent cholangiocarcinoma: a case-control study from the United Kingdom. Dig Dis Sci 2014; 59: 1567-72.
10. Sirica AE,. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005; 41: 5-15.
11. Stancu C, Sima A,. Statins: mechanism of action and effects. J Cell Mol Med 2001; 5: 378-87.
12. Robinson JG, Smith B, Maheshwari N, Schrott H,. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855-62.
13. Wang CY, Liu PY, Liao JK,. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
14. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT, Olsen JH,. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643-7.
15. Kuoppala J, Lamminpaa A, Pukkala E,. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-32.
16. Osmak M,. Statins and cancer: current and future prospects. Cancer Lett 2012; 324: 1-12.
17. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ,. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-94.
18. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W,. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-32.
19. Tsan YT, Lee CH, Wang JD, Chen PC,. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-30.
20. Carey FJ, Little MW, Pugh TF, Ndokera R, Ing H, Clark A, Dennison A, Metcalfe MS, Robinson RJ, Hart AR,. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Dig Dis Sci 2013; 58: 3308-12.
21. Chiu HF, Chang CC, Ho SC, Wu TN, Yang CY,. Statin use and the risk of pancreatic cancer: a population-based case-control study. Pancreas 2011; 40: 669-72.
22. Alexandre L, Clark AB, Bhutta HY, Holt S, Lewis MP, Hart AR,. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology 2014; 146: 661-8.
23. Singh PP, Singh S,. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1721-30.
24. Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY,. Statins are associated with a reduced risk of gastric cancer: a population-based case-control study. Am J Gastroenterol 2011; 106: 2098-103.
25. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE,. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006; 98: 69-72.
26. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G,. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92.
27. Cheng MH, Chiu HF, Ho SC, Yang CY,. Statin use and the risk of female lung cancer: a population-based case-control study. Lung Cancer 2012; 75: 275-9.
28. Khurana V, Bejjanki HR, Caldito G, Owens MW,. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131: 1282-8.
29. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM,. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006; 24: 4808-17.
30. Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7: e29849.
31. Cheng TM,. Taiwan's National Health Insurance system: high value for the dollar. In: Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan, eds, Okma KGH, Crivelli L,. New Jersey: World Scientific, 2009; 71-204.
32. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R,. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
33. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC,. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31: 1514-21.
34. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T,. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004; 15: 419-28.
35. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E,. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-25.
36. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE,. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005; 165: 2264-71.
37. Kaye JA, Jick H,. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-7.
38. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S,. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007; 115: 27-33.
39. Murai T, Maruyama Y, Mio K, Nishiyama H, Suga M, Sato C,. Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration. J Biol Chem 2011; 286: 1999-2007.
40. Miller T, Yang F, Wise CE, Meng F, Priester S, Munshi MK, Guerrier M, Dostal DE, Glaser SS,. Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity. Dig Liver Dis 2011; 43: 395-403.
41. Kamigaki M, Sasaki T, Serikawa M, Inoue M, Kobayashi K, Itsuki H, Minami T, Yukutake M, Okazaki A, Ishigaki T, Ishii Y, Kosaka K, Chayama K,. Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells. Int J Oncol 2011; 39: 561-8.